|
1
|
White NJ: Qinghaosu (artemisinin): the
price of success. Science. 320:330–334. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lu JJ, Meng LH, Cai YJ, et al:
Dihydroartemisinin induces apoptosis in HL-60 leukemia cells
dependent of iron and p38 mitogen-activated protein kinase
activation but independent of reactive oxygen species. Cancer Biol
Ther. 7:1017–1023. 2008. View Article : Google Scholar
|
|
3
|
Efferth T, Sauerbrey A, Olbrich A, et al:
Molecular modes of action of artesunate in tumor cell lines. Mol
Pharmacol. 64:382–394. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Efferth T, Olbrich A and Bauer R: mRNA
expression profiles for the response of human tumor cell lines to
the antimalarial drugs artesunate, arteether, and artemether.
Biochem Pharmacol. 64:617–623. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li LN, Zhang HD, Yuan SJ, Tian ZY, Wang L
and Sun ZX: Artesunate attenuates the growth of human colorectal
carcinoma and inhibits hyperactive Wnt/beta-catenin pathway. Int J
Cancer. 121:1360–1365. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jiao Y, Ge CM, Meng QH, Cao JP, Tong J and
Fan SJ: Dihydroartemisinin is an inhibitor of ovarian cancer cell
growth. Acta Pharmacol Sin. 28:1045–1056. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen T, Li M, Zhang R and Wang H:
Dihydroartemisinin induces apoptosis and sensitizes human ovarian
cancer cells to carboplatin therapy. J Cell Mol Med. 13:1358–1370.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tan W, Lu J, Huang M, et al: Anti-cancer
natural products isolated from chinese medicinal herbs. Chin Med.
6:272011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mercer AE, Maggs JL, Sun XM, et al:
Evidence for the involvement of carbon-centered radicals in the
induction of apoptotic cell death by artemisinin compounds. J Biol
Chem. 282:9372–9382. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Efferth T, Benakis A, Romero MR, et al:
Enhancement of cytotoxicity of artemisinins toward cancer cells by
ferrous iron. Free Radic Biol Med. 37:998–1009. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Efferth T: Molecular pharmacology and
pharmacogenomics of artemisinin and its derivatives in cancer
cells. Curr Drug Targets. 7:407–421. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Singh NP and Lai H: Selective toxicity of
dihydroartemisinin and holotransferrin toward human breast cancer
cells. Life Sci. 70:49–56. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lu JJ, Chen SM, Zhang XW, Ding J and Meng
LH: The anti-cancer activity of dihydroartemisinin is associated
with induction of iron-dependent endoplasmic reticulum stress in
colorectal carcinoma HCT116 cells. Invest New Drugs. 29:1276–1283.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lu YY, Chen TS, Qu JL, Pan WL, Sun L and
Wei XB: Dihydroartemisinin (DHA) induces caspase-3-dependent
apoptosis in human lung adenocarcinoma ASTC-a-1 cells. J Biomed
Sci. 16:162009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen H, Sun B, Pan S, Jiang H and Sun X:
Dihydroartemisinin inhibits growth of pancreatic cancer cells in
vitro and in vivo. Anticancer Drugs. 20:131–140. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu JJ, Meng LH, Shankavaram UT, et al:
Dihydroartemisinin accelerates c-MYC oncoprotein degradation and
induces apoptosis in c-MYC-overexpressing tumor cells. Biochem
Pharmacol. 80:22–30. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Du JH, Zhang HD, Ma ZJ and Ji KM:
Artesunate induces oncosis-like cell death in vitro and has
antitumor activity against pancreatic cancer xenografts in vivo.
Cancer Chemother Pharmacol. 65:895–902. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li W, Mo W, Shen D, et al: Yeast model
uncovers dual roles of mitochondria in action of artemisinin. PLoS
Genet. 1:e362005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Reungpatthanaphong P and Mankhetkorn S:
Modulation of multidrug resistance by artemisinin, artesunate and
dihydroartemisinin in K562/adr and GLC4/adr resistant cell lines.
Biol Pharm Bull. 25:1555–1561. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu JJ, Chen SM, Ding J and Meng LH:
Characterization of dihydroartemisinin-resistant colon carcinoma
HCT116/R cell line. Mol Cell Biochem. 360:329–337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
King A, Selak MA and Gottlieb E: Succinate
dehydrogenase and fumarate hydratase: linking mitochondrial
dysfunction and cancer. Oncogene. 25:4675–4682. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li Z, Zhao X, Yang J and Wei Y: Proteomics
profile changes in cisplatin-treated human ovarian cancer cell
strain. Sci China C Life Sci. 48:648–657. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Castagna A, Antonioli P, Astner H, et al:
A proteomic approach to cisplatin resistance in the cervix squamous
cell carcinoma cell line A431. Proteomics. 4:3246–3267. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lai MY, Hour MJ, Wing-Cheung Leung H, Yang
WH and Lee HZ: Chaperones are the target in aloe-emodin-induced
human lung nonsmall carcinoma H460 cell apoptosis. Eur J Pharmacol.
573:1–10. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen ST, Pan TL, Tsai YC and Huang CM:
Proteomics reveals protein profile changes in doxorubicin--treated
MCF-7 human breast cancer cells. Cancer Lett. 181:95–107. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cappello F, Conway de Macario E, Marasa L,
Zummo G and Macario AJ: Hsp60 expression, new locations, functions
and perspectives for cancer diagnosis and therapy. Cancer Biol
Ther. 7:801–809. 2008. View Article : Google Scholar : PubMed/NCBI
|
